| Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC) (NCT07143955) | The First Hospital of Hebei Medical University | 2022-05-01 |
| A Prospective Observational Study on Efficacy of TARE for Early Stage HCC (NCT07278102) | Seoul National University Hospital | 2022-03-28 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483) | Exelixis | 2021-12-14 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC (NCT07598331) | The First Hospital of Jilin University | 2021-06-01 |
| TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion (NCT07075562) | The First Hospital of Hebei Medical University | 2021-06-01 |
| A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (NCT05022927) | Chugai Pharmaceutical | 2021-06-01 |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (NCT04639180) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-01 |
| Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) (NCT04601428) | Koo Foundation Sun Yat-Sen Cancer Center | 2021-01-26 |
| Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis (NCT06663904) | First Affiliated Hospital, Sun Yat-Sen University | 2021-01-01 |
| The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study (NCT07272265) | Sun Yat-sen University | 2020-10-28 |
| Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function (NCT04522908) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-12 |
| FAST (Focused Abbreviated Screening Technique)-MRI Study (NCT04539717) | Icahn School of Medicine at Mount Sinai | 2020-08-17 |
| Liver Cancer Registry Platform (NCT04510740) | iOMEDICO AG | 2020-08-09 |
| Y90 Radiation Segmentectomy vs SBRT for HCC (NCT04235660) | Indiana University | 2020-07-22 |
| A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer (NCT06636435) | Chiome Bioscience Inc. | 2020-06-01 |
| HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC (NCT07700082) | Anhui Provincial Hospital | 2020-01-01 |
| A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches. (NCT06626724) | Jian You | 2020-01-01 |
| Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC (NCT04241523) | Shanghai Zhongshan Hospital | 2020-01-01 |
| Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma (NCT04227808) | Shanghai Zhongshan Hospital | 2019-12-12 |
| The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors (NCT04044326) | National Taiwan University Hospital | 2019-09-01 |
| Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma (NCT05889949) | Sun Yat-sen University | 2019-06-01 |
| IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (NCT03753659) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-05-09 |
| Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) (NCT03510871) | National Health Research Institutes, Taiwan | 2019-02-12 |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT03735628) | Bayer | 2018-10-17 |
| Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin (NCT03452553) | Boston Scientific Corporation | 2018-07-01 |
| Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions (NCT06881446) | Zhongda Hospital | 2018-06-01 |
| Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC (NCT06876753) | Zhongda Hospital | 2018-06-01 |
| Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis (NCT06881433) | Zhongda Hospital | 2018-06-01 |
| CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC (NCT07449065) | First Affiliated Hospital, Sun Yat-Sen University | 2018-06-01 |
| Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection (NCT05213637) | Chinese PLA General Hospital | 2018-04-25 |
| Study of BGB-A317 in Participants With Previously Treated Unresectable HCC (NCT03419897) | BeiGene | 2018-04-09 |
| Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma (NCT07562763) | Anhui Provincial Hospital | 2018-01-01 |
| A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) (NCT03412773) | BeiGene | 2017-12-18 |
| TACE for HCC by TANDEM and Idarubicin (NCT03349957) | University Hospital, Montpellier | 2017-12-01 |
| The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects (NCT03236649) | Beijing Shenogen Biomedical Co., Ltd | 2017-09-20 |
| A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) (NCT03071094) | Transgene | 2017-07-27 |
| Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma (NCT02834546) | University Hospital, Bordeaux | 2017-07-25 |
| The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG (NCT03138239) | Tel-Aviv Sourasky Medical Center | 2017-07-02 |
| Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI (NCT03267290) | National Taiwan University Hospital | 2017-07-01 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies (NCT03144661) | Incyte Corporation | 2017-05-25 |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC (NCT03516071) | Zai Lab (Shanghai) Co., Ltd. | 2017-05-17 |
| Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR) (NCT02921139) | Dalin Tzu Chi General Hospital | 2016-11-01 |
| Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (NCT02562755) | SillaJen, Inc. | 2015-10-01 |
| A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma (NCT02508467) | Blueprint Medicines Corporation | 2015-07-31 |
| Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis (NCT02794805) | Meridian Bioscience, Inc. | 2015-06-01 |
| Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation (NCT07418138) | Hu Liangshuo | 2015-01-01 |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression (NCT02325739) | Novartis Pharmaceuticals | 2014-12-29 |
| Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt (NCT02990351) | Ain Shams University | 2014-12-01 |
| Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study (NCT02188901) | Yonsei University | 2014-10-15 |
| Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC (NCT02406508) | Delcath Systems Inc. | 2014-10-01 |
| Can Quantitative MRI After cTACE Help Predict Survival ? (NCT02173119) | Medical College of Wisconsin | 2014-08-01 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma (NCT01972672) | Beijing Shenogen Biomedical Co., Ltd | 2013-10-01 |
| A Study of DC-CIK to Treat Hepatocellular Carcinoma (NCT01821482) | Guangxi Medical University | 2013-05-01 |
| A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (NCT01761266) | Eisai Limited | 2013-03-01 |
| Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension (NCT01642446) | Sun Yat-sen University | 2013-01-01 |
| Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score (NCT07687758) | Siriraj Hospital | 2013-01-01 |
| Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma (NCT07703735) | Seoung Hoon Kim | 2012-01-01 |
| Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI (NCT01433016) | Meridian Bioscience, Inc. | 2011-11-01 |
| A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma (NCT01247298) | University of Alabama at Birmingham | 2010-10-01 |
| AI Multitask Model for HCC Treatment (NCT07157085) | Sun Yat-sen University | 2008-01-01 |
| A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer (NCT00355238) | Bristol-Myers Squibb | 2006-12-31 |
| Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation (NCT06799468) | European Hepatocellular Cancer Liver Transplant Group | 2003-01-01 |
| Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval (NCT06751524) | Agenus Inc. | |